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To catalyze the hydrolysis of their natural sub-
strates, sulfatases must be posttranslationally ac-
tivated. A consensus sequence in their catalytic 
domain contains a cysteine that is modified 
into  formylglycine  by  the  formylglycine- 
generating enzyme encoded by the sulfatase modi­
fying  factor 1 (SUMF1) gene (Schmidt et al., 1995; 
Cosma et al., 2003; Dierks et al., 2003). SUMF1 
exerts its activity within the ER; however, it 
can also be secreted and taken up by distant 
cells and tissues, where it relocalizes in the ER 
as an active enzyme (Zito et al., 2007). Multi-
ple  sulfatase  deficiency  (MSD)  is  a  human 
monogenic disorder in which all of the sulfa-
tase  activities  are  simultaneously  defective 
(Hopwood and Ballabio, 2001). Patients with 
MSD have mutations in SUMF1 (Cosma et al., 
2004). A Sumf1/ strain has been generated as 
a mouse model of MSD, and it shows a com-
plete loss of sulfatase activities, early mortality, 
congenital growth retardation, skeletal abnor-
malities, neurological defects, and a generalized 
inflammatory process in many organs (Settembre 
et al., 2007).
These Sumf1/ mice represent an impor-
tant resource to study developmental defects 
associated with SUMF1 lack of function. In-
deed, SUMF1 also has putative activity during 
development specification. To date, 17 differ-
ent sulfatases have been described in humans, 
and  all  are  activated  by  SUMF1  (Sardiello   
et al., 2005). Among this large sulfatase family, 
Sulf1 and Sulf2 are localized on the cell surface 
and catalyze hydrolysis of the 6-O-sulfate of the 
N-acetyl glucosamines of heparan during deg-
radation of heparan sulfate proteoglycans (HSPGs; 
Morimoto-Tomita  et  al.,  2002).  Wingless 
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Self-renewal and differentiation of hematopoietic stem cells (HSCs) are balanced by the 
concerted activities of the fibroblast growth factor (FGF), Wnt, and Notch pathways, which 
are tuned by enzyme-mediated remodeling of heparan sulfate proteoglycans (HSPGs). 
Sulfatase modifying factor 1 (SUMF1) activates the Sulf1 and Sulf2 sulfatases that  
remodel the HSPGs, and is mutated in patients with multiple sulfatase deficiency. Here, we 
show that the FGF signaling pathway is constitutively activated in Sumf1/ HSCs and 
hematopoietic stem progenitor cells (HSPCs). These cells show increased p-extracellular 
signal-regulated kinase levels, which in turn promote -catenin accumulation. Constitutive 
activation of FGF signaling results in a block in erythroid differentiation at the chromato-
philic erythroblast stage, and of B lymphocyte differentiation at the pro–B cell stage.  
A reduction in mature myeloid cells and an aberrant development of T lymphocytes are also 
seen. These defects are rescued in vivo by blocking the FGF pathway in Sumf1/ mice. 
Transplantation of Sumf1/ HSPCs into wild-type mice reconstituted the phenotype of the 
donors, suggesting a cell autonomous defect. These data indicate that Sumf1 controls HSPC 
differentiation and hematopoietic lineage development through FGF and Wnt signaling.
© 2010 Buono et al.  This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months   
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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modulation of gene targets of both the Wnt and Notch path-
ways (Trowbridge et al., 2006).
Interestingly, the activities of Sulf1 and Sulf2 modulate 
Wnt signaling by modifying the sulfation state of the hepa-
ran sulfates contained in HSPGs, thereby impairing fibro-
blast growth factor (FGF) signaling. Crystal structure studies 
have demonstrated that binding of FGF1 and FGF2 to the 
FGF receptor is stabilized by 6-O-sulfation of the heparan 
sulfates of the HSPGs (Pellegrini et al., 2000). Thus, through 
desulfation of these heparan sulfates, hSulf1 can down- 
regulate  FGF-dependent  extracellular  signal-regulated  kinase 
(ERK) kinase activity (Lai et al., 2003). FGF1 and FGF2 
signaling preserves ex vivo expansion of primitive HSCs 
(Yeoh et al., 2006).
Thus, an intriguing question is raised: does Sumf1 act as a 
master regulator of the signaling of the Wnt and FGF path-
ways through activation of Sulf1 and/or Sulf2, resulting, in 
turn, in modulation of developmental signals and of HSC 
self-renewal and cell lineage commitment?
Here, we show that SUMF1 has a role in promoting cell 
lineage  commitment.  Sumf1/  HSCs  and  hematopoietic 
stem progenitor cells (HSPCs) show constitutive activation 
of the FGF signaling pathway, and the consequent increase in 
p-ERK leads to GSK3- phosphorylation and -catenin ac-
cumulation. In turn, Notch is also accumulated. These al-
tered signaling pathways lead to a block of erythroid, myeloid, 
and lymphoid differentiation in Sumf1/ mice. We also pro-
vide evidence that Sulf2/ mice recapitulates the Sumf1/ 
BM phenotype up to a certain point. In contrast, Ids/ and 
Sgsh/ mice, which are two mouse loss-of-function sulfatase 
models, did not show any relevant hematopoietic differentia-
tion defects. Furthermore, upon transplantation of Sumf1/ 
HSPCs into lethally irradiated WT mice, there was impaired 
differentiation  of  the  donor  cells,  which  recapitulates  the   
hematopoietic defects seen in the Sumf1/ mice; further-
more, in the recipient mice, a decrease in the frequency of 
LT-HSCs was observed. These findings confirm that the dif-
ferentiation impairment of the mutant HSCs and their prog-
eny is caused by SUMF1 loss of function, and not by different 
environmental features.
RESULTS
FGF and canonical Wnt signaling pathways  
are constitutively activated in HSPCs of Sumf1/ mice
HSC differentiation and self-renewal are modulated by dif-
ferent mitotic stimuli. Thus, we analyzed whether the Wnt–
-catenin and FGF signaling pathways are altered in HSPCs 
from Sumf1/ mice. The HSPCs were purified from the 
BM of 3-wk-old Sumf1/ mice, and from age-matched WT 
mice, by lineage-negative selection. Sulf1 and Sulf2 activities 
were  fully  impaired  in  homogenates  of  Sumf1/  HSPCs 
(Fig. 1 A). Sulf1 and Sulf2 inactivation leads to an increase in 
the signaling of FGF, which is caused by stabilization of the 
HSPG–FGFR–FGF trimeric complex (Wang et al., 2004; 
Lamanna et al., 2008). Indeed, there was also increased phos-
phorylation of ERK, a downstream effector of FGF signaling, 
(Wg)/Wnt belongs to a family of secreted morphogenic pro-
teins that control tissue-specific cell fate decisions during em-
bryogenesis, and that bind to the heparan sulfate moieties on 
the cell surface of HSPGs (Logan and Nusse, 2004; Bejsovec, 
2005). QSulf, the avian orthologue of human Sulf (hSulf), 
removes the sulfate from heparan sulfate, and releases Wnt 
from HSPGs. This released Wnt associates with Frizzled (Fz) 
and LRP5/6 receptors, resulting in inactivation of a multi-
protein destruction complex, which is composed of glycogen 
synthase kinase-3 (GSK-3), Axin2, and adenomatous poly-
posis coli (APC). This inactivation leads to translocation of   
-catenin into the nucleus, where it activates several target 
genes (Hoppler and Kavanagh, 2007). In addition to its role 
in embryogenesis, Wnt is involved in controlling prolifera-
tion of stem cells. Wnt3a belongs to the Wnt family, and has 
been shown to enhance self-renewal and maintain totipotency/
multipotency  of  embryonic  stem  cells  and  hematopoietic 
stem cells (HSCs), respectively, through accumulation of   
-catenin in the cell nucleus (Reya et al., 2003; Anton   
et al., 2007). Furthermore, transplantation of Wnt3a-treated 
BM increases the survival of lethally irradiated mice (Willert 
et al., 2003).
HSCs reside in the BM and are a rare population of adult 
pluripotent stem cells that have the dual capability of self- 
renewal and differentiation into all blood cell lineages. Based 
on their ability to self-renew, HSCs can be defined as long-
term (LT-HSCs) and short-term (ST-HSCs) HSCs. LT-HSCs 
have extensive self-renewal abilities and sustain life-long he-
matopoiesis, whereas ST-HSCs represent a more committed 
population with short self-renewal potential (Laiosa et al., 
2006a). That Wnt signaling stimulates proliferation and self-
renewal of HSCs was suggested >10 yr ago (Austin et al., 
1997). More recently, it has been shown that exposure of 
HSCs to Wnt antagonists in vitro reduces their proliferation 
ability and that Bcl-2 transgenic HSCs transduced with retro-
viral vectors encoding -catenin can fully reconstitute the 
hematopoietic compartments of recipients (Reya et al., 2003). 
On  the  other  hand,  stable  expression  of  -catenin  from   
the Rosa26 locus in transgenic mice led to loss of HSC re-
population and multilineage differentiation potential (Kirstetter 
et al., 2006). Mice with -catenin deletion in their HSCs 
show  normal  hematopoiesis  (Cobas  et  al.,  2004).  These   
apparently contradictory data might reveal some novel as-
pects of the function of the Wnt signaling pathway. Indeed, 
it appears that different and specific amounts of -catenin 
confer divergent phenotypes and differentiation capabilities 
to HSCs.
In addition, a fine-tuned balance between different sig-
naling pathways might be important to control self-renewal 
and differentiation of HSCs. The Notch and Wnt pathways 
have been shown to act in synergy to maintain the HSC 
pool, with Wnt being important to induce proliferation and 
support viability of HSCs, and Notch being important in the 
maintenance of HSCs in an undifferentiated state (Duncan   
et al., 2005). Furthermore, in vivo inhibition of GSK-3 
augments the repopulation abilities of transplanted HSCs via JEM VOL. 207, August 2, 2010 
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To  demonstrate  the  constitutive 
activation of FGF and Wnt signaling 
in HSCs, the c-kit+, lineage, and 
Sca1+ (KLS) cell fraction of HSPCs 
was purified from WT and Sumf1/ 
mice.  These  KLS  cells  were  then 
transduced  with  lentiviruses  (LVs) 
carrying 4X -catenin or an ERK- 
responsive  element  upstream  of  a 
minimal CMV promoter controlling 
enhanced  GFP  (eGFP)  expression. 
eGFP  expression  was  quantified  as 
percentages of eGFP+ cells within the KLS cells (Fig. 2 A), 
LT-HSCs (Kit+, Lin, Sca1+, and CD150+; Fig. 2 B) and 
ST-HSCs (Kit+, Lin, Sca1+, and CD150; Fig. 2 C). The 
FGF and Wnt/-catenin pathways were constitutively acti-
vated in all of the Sumf1/ cell populations analyzed, as 
demonstrated by the increased frequency of GFP+ cells in 
these populations, as compared with their WT counterparts.
Finally,  we  tested  the  HSPC  clonogenic  potential  by 
counting CFUs of WT and Sumf1/ HSPCs obtained with 
the colony-forming cell assay. Here, 30% less total CFUs 
were originated by Sumf1/ HSPCs, as compared with WT 
HSPCs. There were no differences in the morphologies and 
amounts of erythroid CFUs (CFU-E), but a significant re-
duction in myeloid CFUs (CFU-GM; Fig. 2 D), although 
the ratios of both CFU-E and CFU-GM with respect to the 
total number of colonies was comparable (Fig. 2 E).
These data demonstrate that the FGF and Wnt/-catenin 
pathways are constitutively active in HSPCs from Sumf1/ 
mice, and also it might be possible that SUMF1 modulates 
these pathways through Sulf1 and Sulf2 activities.
Increased ERK phosphorylation in Sumf1/ HSPCs controls 
activation of the Wnt–-catenin signaling pathway
We  next  asked  whether  accumulation  of  -catenin  in 
Sumf1/ HSPCs is caused by increased phosphorylation of 
ERK. Inactivation of GSK-3, the kinase that is part of the 
-catenin destruction complex, occurs via its phosphorylation. 
both in freshly isolated Sumf1/ HSPCs (Fig. 1 B) and in 
Sumf1/ HSPCs cultured without growth-factor stimula-
tion (Fig. 1 C, right). As expected, no differences were seen 
when the cells were cultured in an enriched medium, be-
cause the added growth factors can themselves modulate sev-
eral signaling pathways (Fig. 1 C, left). The FGF signaling 
pathway was specifically activated in the Sumf1/ HSPCs 
because there was increased phosphorylation of the down-
stream effector FSR2 (Kouhara et al., 1997) and increased 
transcription of GPC3, which positively modulates the path-
way (Lai et al., 2008; Fig. S1, A and B).
Surprisingly, accumulation of -catenin was seen in both 
freshly isolated and cultured Sumf1/ HSPCs (Fig. 1, B   
and C, right). This was not expected; indeed, inactivation of 
Sulf1 and Sulf2 should result in the inactivation of the ca-
nonical Wnt pathway, with the consequent -catenin deg-
radation (Ai et al., 2003). The accumulation of -catenin 
and the increase in ERK phosphorylation were specifically 
caused  by  inactivation  of  both  Sulf1  and  Sulf2  in  the 
Sumf1/ HSPCs, as confirmed by the analysis with HSPCs 
isolated from the BM of Sulf1/ Sulf2/double-KO mice 
(Fig. 1 D, left). In contrast, there were no differences in the 
levels of p-ERK and in -catenin accumulation in retrieved 
HSPCs from the BM of MPSIIIA (deficient in SGSH sulfa-
tase) and MPSII (deficient in IDS sulfatase) mice, as com-
pared with WT mice (Fig. 1, E and F), thus excluding a role 
of the other sulfatases.
Figure 1.  Constitutive activation of FGF 
and Wnt signaling in Sumf1/ HSPCs.  
(A) Sulf1 and Sulf2 enzymatic activities in total 
homogenates of WT and Sumf1/ HSPCs. 
The activities are reported as nanomole/hour/
milligram protein, as indicated (means ± SD; 
n = 3). (B–F) Western blots with the indicated 
antibodies of total homogenates from freshly 
isolated WT and Sumf1/ HSPCs (B); cultured 
WT and Sumf1/ HSPCs (C); WT, Sulf1/, 
Sulf2/, and Sulf1/2 double-KO HSPCs (D); 
WT and Sgsh/ HSPCs (E); and WT and Ids/ 
HSPCs (F). Data are representative of three in-
dependent experiments (n = 3 for each mouse 
model). Cells were cultured or not with re-
combinant cytokines, as indicated. The loading 
controls were anti-actin and anti-ERK1/ERK2.1650 Sumf1 controls hematopoiesis | Buono et al.
and Western blotting was then performed on the protein   
homogenates.  Phosphorylation  of  ERK  was  completely 
abolished in these UO126-treated cells, and GSK3- phos-
phorylation was also blocked. Remarkably, -catenin did not 
accumulate in these cells, and remained at levels comparable 
to WT HSPCs (Fig. 3 A, lanes 1–3).
In addition, we examined the accumulation 
of two transcription factors that regulate ery-
throid  and  myeloid  differentiation:  C/EBP 
and GATA-1 (Laiosa et al., 2006b; Tsai et al., 
1989).  Semiquantitative  PCR  analysis  and 
Western blotting showed that both C/EBP 
and GATA-1 accumulate in Sumf1/ HSPCs 
(Fig. S2 and Fig. 3 A, lane 2). Their levels were 
substantially  diminished  in  UO126-treated 
Sumf1/ HSPCs, and were comparable to 
those  of  WT  HSPCs  (Fig.  3  A,  lanes  1–3). 
Thus, C/EBP was up-regulated here by in-
creased levels of p-ERK, as has been previously 
shown (Prusty et al., 2002). Interestingly, we 
Although this can be mediated by activation of the canonical 
Wnt pathway, it can be mediated also by p-ERK (Ding et al., 
2005). We tested for the latter possibility by inhibiting   
p-ERK  with  the  MEK1/2  inhibitor  UO126  (Fig.  3  A). 
Sumf1/ HSPCs were cultured in the presence of UO126, 
Figure 2.  Constitutive activation of FGF 
and Wnt signaling in the KLS cells of 
Sumf1/ mice. Percentage of cells express-
ing -catenin (LEF/TCF) and ERK GFP reporters 
in gated Sumf1/ (KO) KLS (Lin kit+ Sca1+; 
A), LT-HSC (Lin kit+ Sca1+ CD150+; B), and 
ST-HSC (Lin kit+ Sca1+ CD150; C) subsets 
expressed as fold relative to WT. Data are 
mean ± SE of three independent experiments 
(n = 3 for each group with technical tripli-
cates). (D) WT and KO HSPC colony assays, 
analyzed as total CFU (CFUtot), erythroid CFU 
(CFU-E), and myeloid CFU (CFU-GM). Data are 
mean ± SE of three independent experiments 
(n = 3 for each group with technical tripli-
cates). (E) WT and KO CFU-E and CFU-GM, as 
percentages of total CFUs.
Figure 3.  FGF-mediated activation of Wnt and 
Notch1 signaling pathways in HSPCs and MSCs from 
Sumf1/ mice. (A) Western blot of total lysates from 
WT and Sumf1/ (KO) HSPCs cultured without or with 
100 µM UO126, 100 ng/ml Dkk1, or 100 ng/ml bFGF, as 
indicated. The loading controls were anti-actin, anti-
ERK1/ERK2, and anti-GSK3. The images are representa-
tive of four independent experiments (n = 4 for each 
group). (B–D) Quantitative RT-PCR analyses of Axin-2 (B), 
Notch1 (C), and Hes1 (D) in WT and KO HSPCs grown 
under standard conditions or treated with UO126, Dkk1, 
and bFGF, as in A. Data are means ± SE (n = 3 for each 
group; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.005). (E) Western 
blot of protein extracts from WT and KO MSCs cultured 
without or with 100 µM UO126. (F) Quantitative RT-PCR 
analysis of WT and KO MSCs, as in B–D, including Deltex-1. 
E and F are representative of two independent experi-
ments (n = 4 for each group).JEM VOL. 207, August 2, 2010 
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increased  p-ERK,  accumulation  of 
-catenin, and a consequent increased 
transcription of Notch1, Deltex­1, Hes­1, 
and Axin2 (Fig. 3, E and F). Inhibition 
of ERK phosphorylation by UO126 in Sumf1/ MSCs led to 
reduced accumulation of -catenin and down-regulation of   
target genes (Fig. 3, E and F).
These data indicate that SUMF1 controls the FGF signal-
ing pathway, which in turn also regulates the amount of   
-catenin accumulation, also in the stromal component of the 
HSC niche.
SUMF1 loss of function results in a multilineage 
differentiation block
Next, we investigated whether altered Wnt and FGF signal-
ing pathways and the accumulation of c/EBP and GATA-1 
transcription factors can result in differentiation impairment 
of HSCs in Sumf1/ mice.
We first quantified the total number of cells in the BM, 
spleen, and thymus of Sumf1/ mice, as compared with age-
matched WT littermates, with organ cellularity adjusted accord-
ing to body or organ weights (caused by the very low body 
weights of the mutant mice). There was low cellularity in the 
hematopoietic organs of Sumf1/ mice, as compared with WT 
controls (Fig. S3, tables I and II). Similar differences in cellularity 
were also seen in the spleen and thymus of Sulf2/ mice, al-
though these were not seen in the Sulf1/, Ids/, and Sgsh/ 
mice (Fig. S3, tables III and IV, and not depicted).
We then studied the phenotype of the BM of Sumf1/ 
mice. A cohort of ≥14 Sumf1/ mice and age- and sex-
matched WT mice (4 wk old) were sacrificed, and their BM 
cells were flushed from their long bones and characterized by 
multichannel FACS analysis, for the expression of lineage/
differentiation-stage markers.
Erythroid  differentiation  normally  progresses  from 
CD71+Ter119low/  pro-erythroblasts  through  CD71+Ter119+ 
basophilic erythroblasts, CD71low Ter119+ chromatophilic 
also saw a marked p-ERK–dependent increase in GATA-1 
levels. Conversely, there were similar levels of -catenin,   
p-ERK,  and  c/EBP  in  Sumf1/  HSPCs  that  was  not   
dependent on whether they were treated with Dkk1, a Wnt 
pathway inhibitor that acts on the Frizzled receptor (Bafico   
et al., 2001; Fig. 3 A, lanes 2 and 4). As expected, bFGF treat-
ment of HSPCs increased p-ERK and p-GSK3- even fur-
ther, in respect to untreated Sumf1/ cells; in turn, c/EBP, 
GATA-1, and -catenin accumulated accordingly (Fig. 3 A, 
lanes 2 and 5). In addition, Axin2 and Notch1, which are   
-catenin target genes, and Hes­1, a Notch1 target gene, were 
up-regulated in Sumf1/ HSPCs, in respect to WT HSPCs. 
These  levels  were  diminished  by  treating  the  cells  with 
UO126, but not with Dkk1, whereas FGF treatment resulted 
in an increase in the expression levels in respect to the un-
treated Sumf1/ HSPCs (Fig. 3, B–D). These data clearly 
show that SUMF1 inactivation results in an increase in   
ERK phosphorylation, which in turn leads to -catenin,   
c/EBP, and GATA-1 accumulation. Sulf1/2/ double-
KO mice also showed c/EBP and GATA-1 accumulation 
(unpublished data).
HSCs are regulated by extrinsic cues, such as a variety of 
cytokines, growth factors, and ligands, and multiple develop-
mental  signaling  pathways.  The  regulation  of  Wnt,  BMP, 
Notch, Hedgehog, and FGF signaling pathways can contribute 
to the modulation of HSC-niche activity and can influence the 
quiescence state and mobilization of HSCs, and their recruit-
ment to the vascular niche (Blank et al., 2008). Thus, we in-
vestigated  the  activation  of  the  Wnt/-catenin  and  FGF 
pathways in mesenchymal stromal cells (MSCs), which are 
nonhematopoietic cells that support HSC activities and func-
tions in the niche. The MSCs isolated from the total BM 
of WT and Sumf1/ littermates at 3 wk of age showed   
Figure 4.  Erythroid and myeloid differen-
tiation in Sumf1/ mice. (A) Erythroid  
differentiation in BM of WT (n = 15) and 
Sumf1/ (KO; n = 14) mice. Charts represent 
the percentages of marker +/ cells according 
to legend on Y axes; each dot represents one 
mouse, means are shown. Representative dot 
plots are shown below. Numbers in dot plots 
indicate percentage of cells in each gate.  
(B) The percentages of Ter119+ erythroid cells in 
the spleen of WT (n = 8) and KO (n = 7) mice. 
(C) Monocyte (CD11b+ CD115+) and granulo-
cyte (CD11b+ CD115) frequencies in the BM 
of WT (n = 13) and KO (n = 12) mice. (D) Gran-
ulocyte (Gr+) frequency in the spleen of WT  
(n = 8) and KO (n = 9) mice. Unpaired Student’s 
t test statistical analysis was performed, and  
P values are reported when significant. Each 
experiment was repeated four times.1652 Sumf1 controls hematopoiesis | Buono et al.
myeloid lineages, and that SUMF1 loss of 
function results in a significant loss of erythroid 
and myeloid terminally differentiated cells.
B  lymphocytes  differentiate  in  the  BM 
from a common lymphoid progenitor (CLP) 
through a series of well-defined intermediates. 
We analyzed the pro–B cell stage (CD127+, 
B220low, IgM) in the BM of Sumf1/ mice, 
in comparison with WT littermates: there was 
an accumulation of pro–B cells, a reduction in 
immature B cells (CD127, B220low, IgM+), 
and apparently normal percentages of mature 
B cells (B220high, IgM+; Fig. 5 A). However, a 
strong  decrease  in  terminally  differentiated   
B lymphocytes (B220+) was seen in the spleen of mutant mice 
(Fig. 5 B). These data led us to conclude that there was a block 
in maturation of B lymphocytes at the pro–B stage. Absolute   
B cell counts in the spleen confirmed this finding (unpublished 
data), thus weakening the alternative hypothesis, that lack of ter-
minally differentiated B cells is a secondary effect caused by the 
erythroid expansion occurring in the spleen of the Sumf1/ 
mice.  No  differences  were  detectable  in  pro–B  and  mature   
B cells in any of the other mice models analyzed, with the ex-
ception of Sulf2/ mice, in which a slight decrease in immature 
and mature B lymphocytes was seen in the BM, although 
this was in the absence of a defect in mature cells in the spleen. 
(Fig. S5, A and B).
Next, we analyzed T cell development. As with B lym-
phocytes, T cells originate from a CLP, but during differenti-
ation,  the  pro–T  cell  (c-kit+,  CD127+,  CD25,  CD3, 
CD4, and CD8) BM-resident cells migrate into the thymus 
to give rise to mature T lymphocytes. Sumf1/ and WT 
mice had similar pro–T cell percentages in the BM (Fig. 5 C). 
However,  a  reduction  in  immature  double-positive  (DP) 
CD4+ CD8+ thymocytes and an increase in single-positive 
(SP)  CD4+  or  SP  CD8+  thymocytes  were  seen  in  the   
thymus of Sumf1/ mice (Fig. 5 D). The CD4 and CD8   
erythroblasts, and CD71Ter119+/high orthochrotomaphilic 
erythroblasts.  In  the  Sumf1/  BM,  we  saw  accumulation   
of CD71+Ter119low/ pro-erythroblasts and a strong reduction 
in CD71low Ter119+ chromatophilic erythroblasts and mature 
CD71Ter119high orthochrotomaphilic erythroblasts, indicating 
a block in erythroid differentiation (Fig. 4 A). The accumulation 
of erythroblasts in the spleen of Sumf1/ mice might reflect   
a compensatory response to ineffective erythropoiesis, or a   
peripheral accumulation of immature cells (Fig. 4 B). An   
increase in CD71+Ter119low/ pro-erythroblasts was also seen   
in Sulf2/ mice, but not in Sulf1/, Ids/, or Sgsh/ mice 
(Fig. S4, A and B, and not depicted). No differences were   
detected in the percentages of BM CD71lowTer119+, of BM 
CD71–Ter119high, and of spleen Ter119+ cells from these animal 
models (Fig. S4 C). In the BM of Sumf1/ mice, there was also 
a marked reduction in monocytes (CD11b+ and CD115+) and a 
slight decrease in granulocytes (CD11b+ and CD115), as com-
pared with WT mice, with no differences in their percentages in 
the spleen (Gr-1+; Fig. 4, C and D). In contrast, myeloid devel-
opment progressed normally in the Sulf1/, Sulf2/, ids/, 
and sgsh/ mice (unpublished data).
Overall, these data indicate that SUMF1 contributes to 
the regulation of the development of the erythroid and   
Figure 5.  Lymphoid differentiation in Sumf1/ 
mice. (A and B) Differentiation of B cells in BM (A) and 
spleen (B) of WT (n = 13) and Sumf1/ (KO; n = 14) 
mice. (A) Different stages of B cell maturation were 
defined according to expression of IgM, B220, and 
CD127 markers (mean ± SD). (B) B220+ cells in spleen of 
WT (n = 13) and KO (n = 14) mice. (C–E) Differentiation 
of T cells in BM (C) and thymus (D and E) of WT (n = 13) 
and KO (n = 14) mice. (C) Percentages of pro–T cells 
(CD127+ CD3 CD4 CD8/low CD25 c-kit+) in BM. (D) 
Percentages of thymocytes in indicated subsets (repre-
sentative plots are shown below graphs). Each dot rep-
resents one mouse, means are shown. (E) Percentage of 
cells in indicated subsets gated on CD3+ thymocytes. 
Unpaired Student’s t test statistical analysis was per-
formed, and p-values are reported when significant.  
(F) Western blots of total homogenates from WT (n = 6) 
and KO (n = 6) HSPCs with the indicated antibodies. 
Data are representative of six independent experiments.JEM VOL. 207, August 2, 2010 
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were seen in Ids/, Sulf1/, and Sulf2/ mice (unpub-
lished data).
In vivo inhibition of the FGF pathway overcomes  
the SUMF1-dependent multilineage differentiation block
To further demonstrate that the constitutive FGF signaling that 
leads to -catenin accumulation is responsible for the multilin-
eage differentiation block seen in Sumf1/ mice (Figs. 4 and 5), 
we wanted to unlock the differentiation of Sumf1/ terminal 
lineages by inhibiting FGF1 signaling in vivo with SU5402,   
a  specific  FGF1  receptor  antagonist.  Thus,  Sumf1/  mice 
were i.p. injected at postnatal day (P) 7 with a suspension of 
500 µM SU5402 adsorbed onto beads (to allow slow SU5402 
release). The mice were then analyzed at P21–P27 (Fig. 7 A). 
Upon SU5402 treatment, the frequency of intermediate pre-
cursors and terminally differentiated CD71Ter119+ cells   
significantly increased in the BM of Sumf1/ mice, demonstrat-
ing a rescue of the block of erythroid lineage differentiation 
(Fig. 7 B). Similarly, the myeloid lineage was unlocked, and 
comparable frequencies of monocytes and granulocytes were 
seen, in respect to those in the BM of WT littermates (Fig. 7 C). 
Moreover, SU5402 also increased the mature B lymphocytes 
antigens are expressed only after CD3 (a TCR accessory pro-
tein; Clevers et al., 1988; Teh et al., 1988). By looking at the 
CD3+ population, no differences in the frequencies of SP 
CD3+ CD4+ and SP CD3+ CD8+ cells were seen in Sumf1/ 
mice, as compared with WT mice, clearly showing the exis-
tence of aberrant Sumf1/ populations of CD4+ and CD8+ 
thymocytes that did not express CD3 (Fig. 5 E). This might 
be caused by accumulation of Notch1 and -catenin in the 
Sumf1/ thymocytes (Fig. 5 F). Indeed, Notch1 has been 
shown to substitute for CD3 expression in promoting devel-
opment of thymocytes from the DP to SP stages (Deftos   
et al., 2000; Michie et al., 2007). In the Sulf1/, Ids/, and 
Sgsh/ mice, pro–T cells, total DP and SP thymocytes, and 
DP and SP cells gated on CD3+ were comparable in fre-
quency to those of WT mice (Fig. S5, C–H, and not de-
picted). However, a slight decrease in DP thymocytes and a 
parallel increase in SP CD4+ cells was seen in Sulf2/ mice 
when gated both on the total population and on the CD3+ 
cells (Fig. S5, F–H). Interestingly, development of invariant 
natural killer T cells, a highly specialized subset of thymo-
cytes, was also severly impaired in the Sumf1/ mice (Plati 
et al., 2009).
The stem/early progenitor cell compartment is not affected 
in bone marrow of Sumf1/ mice
The HSC-enriched KLS compartment, defined as c-kit+, 
Lin, Sca1+, includes LT-HSCs, ST-HSCs, and multipo-
tent progenitor (MPP) cells (Spangrude et al., 1988; Laiosa 
et al., 2006a). The analysis of the lineage-negative HSPC 
population of WT and Sumf1/ mice revealed a similar 
content of KLS cells in the BM (Fig. 6 A). In addition, to 
identify LT-HSCs (c-kit+, Lin, Sca1+, and CD150+), ST-
HSCs, and MPP cells (ST-HSC/MPP: c-kit+, Lin, Sca1+, 
and  CD150),  we  analyzed  the  CD150  marker  in  KLS 
cells. Comparable proportions of LT-HSCs and ST-HSC/
MPP cells were present in the BM of Sumf1/ and WT 
mice (Fig. 6 B).
The HSPC fraction also includes early committed pro-
genitor cells, such as CLPs and common myeloid progenitors 
(CMPs).  The  CLP  population  differentiates  subsequently 
into pro–T and pro–B cells, whereas the CMP population 
generates  megakaryocyte–erythrocyte  progenitors  (MEPs) 
and  granulocyte–monocyte  progenitors  (GMPs;  Morrison 
and Weissman, 1994; Morrison et al., 1995; Kondo et al., 
1997; Akashi et al., 2000; Laiosa et al., 2006a). To evaluate 
the relative frequencies of these progenitor cells, Sumf1/ 
and  WT  HSPCs  were  stained  for  Sca1+,  c-kit+,  CD127, 
CD16, and CD34. Flow cytometry analysis revealed no sig-
nificant differences in the contents of CMPs (Lin, c-kit+, 
Sca1,  CD127,  CD34high,  and  CD16low),  MEPs  (Lin,   
c-kit+, Sca1, CD127, CD34, and CD16low), GMPs (Lin, 
c-kit+, Sca1, CD127, CD34high, and CD16high), and CLPs 
(Lin, c-kit+, Sca1+, and CD127+) in Sumf1/ HSPCs, in 
respect to WT cells; however, the progenitor cells showed 
a tendency to increase in Sumf1/ HSPCs, in respect to the 
WT cells (Fig. 6 C). No major differences in HSPC subfractions 
Figure 6.  Characterization of HSC and progenitor subsets. Percent-
age of Sca1+ c-kit+ HSCs (A) and LT-HSCs (CD150+; B) in lineage-negative 
BM of WT (n = 21) and Sumf1/ (KO; n = 16) mice (each dot represents 1 
mouse; results are expressed as fold relative to WT). Representative plots 
are shown on the right. (C) Percentage of CLPs, common myeloid progeni-
tors (CMPs), megakaryocyte-erythrocyte progenitors (MEPs), and granulo-
cyte-monocyte progenitors (GMPs) in BM of KO mice expressed as fold to 
WT mean (means ± SD; n = 6). Unpaired Student’s t test (A and C) or 
Mann-Whitney (B) statistical analysis were performed, and p-values are 
reported when significant. Each experiment was repeated three times.1654 Sumf1 controls hematopoiesis | Buono et al.
vector carrying GFP cDNA, to fol-
low their long-term fate after trans-
plantation  (Biffi  et  al.,  2004).  LV- 
transduced  HSPCs  (7  ×105)  were 
transplanted  into  lethally  irradiated, 
2-mo-old WT recipient mice. 10 wk after noncompetitive 
transplantation,  the  hematopoietic  organs  were  collected 
and analyzed by flow cytometry, as described above. The 
cells of donor origin were analyzed according to GFP ex-
pression. This analysis showed a considerable reduction in 
the total cell number in the BM, spleen, and thymus of mice 
transplanted with Sumf1/ HSPCs, with respect to mice 
transplanted with WT cells (Fig. 8 A), as also seen in the   
donor mice. Interestingly, the overall engraftment of GFP+ 
Sumf1/ and WT HSPCs were comparable (Fig. 8 B). All 
further analyses were performed on the GFP+ population to 
avoid  confounding  effects  from  residual  autologous  cells. 
When we analyzed terminally differentiated cells in the BM, 
spleen, and thymus of the transplanted mice, a block in ery-
throid lineage differentiation of the Sumf1/ HSPCs trans-
planted mice was clearly seen, as strong reductions in the 
frequencies  of  CD71lowTer119+  chromatophilic  erythro-
blasts and of mature CD71Ter119high orthochrotomaphilic 
erythroblasts  (Fig.  8  C).  Notably,  and  probably  because   
of the limited time of observation (10 wk after the trans-
plant), in these mice we did not detect any accumulation   
of  CD71+Ter119+  cells  in  the  BM,  although  the  same 
in treated mutants, as compared with untreated mice (Fig. 7 D). 
Although SU5402 treatment did not affect the pro–T fre-
quency in the BM (Fig. 7 E), thymocytes developed normally; 
comparable DP and SP T lympocyte frequencies were seen in 
the treated mutants, both for the total (Fig. 7 F) and for elec-
tronically gated CD3+ populations (not depicted), in respect to 
WT mice. We did not observe any correction/restoration of 
the erythrocyte and B lymphocyte proportions in the spleen of 
treated mice, which was probably because we analyzed the 
mice 2–3 wk after SU5402 administration, a time that is too 
early to see any rescue effect (Fig. 7 G).
Collectively,  these  findings  demonstrate  that  SUMF1 
controls hematopoietic lineage differentiation via modulation 
of the FGF pathway.
Sumf1/ HSPCs fail to differentiate in a wild-type  
host, and transplanted mice show the Sumf1/ 
hematopoietic phenotype
To demonstrate that differentiation defects of Sumf1/ HSPCs 
are cell autonomous and independent of the cell niche,   
we transplanted these into WT recipient mice. Purified   
WT HSPCs and Sumf1/ HSPCs were transduced with a LV 
Figure 7.  SU5402-FGFR blocker reverted 
the terminal multilineage differentiation 
blocks in Sumf1/ mice. (A) Experimental 
timeline. Sumf1/ mice were i.p. injected at P7 
with a suspension of FGFR inhibitor adsorbed 
on beads. The animals were then sacrified at 
P21-P27 and BM, spleen and thymus pheno-
type analysis were performed. (B) Erythroid 
differentiation in BM of WT (n = 17), Sumf1/ 
(KO; n = 15) and Sumf1/ KO treated (n = 6; 
KO+D) mice. Charts represent the percentages 
of cells in each subset; each dot represents one 
mouse, means are shown. (C) Monocyte and 
granulocyte frequencies in the WT (n = 12), KO 
(n = 11) and KO-treated (n = 6) mice. (D) B cell 
maturation in WT (n = 7), KO (n = 9), and KO-
treated mice (n = 6), according to expression of 
IgM, B220, and CD127 markers. (E and F) Dif-
ferentiation of T cells in BM (E) and thymus (F) 
of WT (n = 13) and KO (n = 14) and KO-treated 
(n = 6) mice. (E) Percentages of pro–T cells in 
BM of WT (n = 8), KO (n = 8) and KO+D (n = 6). 
(F) Percentages of thymocytes in each subset 
(WT, n = 13; KO, n = 14; drug-treated KO, n = 6). 
(G) B lymphocytes (B220+) and erythrocytes 
(Ter-119+) in the spleen of WT (n = 13), KO  
(n = 14), and treated KO (n = 6) mice. Unpaired 
t test statistical analysis was performed, and  
P values are reported when significant. Analysis 
of two independent experiments.JEM VOL. 207, August 2, 2010 
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mutated cells that might unlock GMP 
progression into differentiation (un-
published data).
Finally,  we  analyzed  the  HSPC 
fraction  in  both  of  these  groups   
of  transplanted  mice.  Interestingly, 
there was a slight increase (although 
not statistically significant) in the fre-
quency  of  KLS  cells  in  the  mice 
transplanted  with  Sumf1/  GFP+  HSPCs  (Fig.  9  A). 
Within the KLS cells, we saw a decrease in the frequency 
of CD150+ LT-HSCs and a consequent increase in the   
ST-HSC/MPP fraction in the group of Sumf1/ HSPC 
transplanted mice (Fig. 9 B), suggesting that the SUMF1 
defect might render primitive HSC more prone to differ-
entiate into ST-HSCs and MPPs. Furthermore, there were 
relevant  increases  in  CLPs  and  CMPs  in  the  Sumf1/ 
HSPC transplanted mice (although, not statistically signifi-
cant; Fig. 9 C).
In  conclusion, 
transplantation  of 
Sumf1/  HSPCs 
reproduces the phe-
notype of Sumf1/ 
mice in a WT host, 
compensatory increase in Ter119+ cells was seen in the spleens 
of the donors (Fig. 8 D).
Impaired B cell development and aberrant T cell develop-
ment were seen in the Sumf1/ HSPCs transplanted mice, 
which showed a decrease in pre–/pro–B cells, low percentages 
of terminally differentiated B cells in the spleen, a reduction in 
DP CD4+ CD8+ cells in the thymus, and an increase in SP 
CD4+ and SP CD8+ thymocytes (Fig. 8, E–G). In addition, as 
for the donor mice, there was aberrant CD3 SP CD4+ and SP 
CD8+, without expression of the TCR accessory protein (un-
published data).
Furthermore, although the number of granulocytes and 
monocytes in the BM were similar in both of these groups of 
transplanted mice, there was a slight decrease in Gr-1+ cells in 
the spleen of the Sumf1/ HSPCs transplanted mice, leading 
us to envision a compensatory mechanism in the BM, with 
Figure 8.  Sumf1/ HSPC differentiation 
in wild-type hosts. (A) Total cell count of 
BM, spleen, and thymus of mice transplanted 
with WT (WT HSCT, n = 8) or Sumf1/ HSPCs 
transduced with GFP-expressing LV (KO HSCT, 
n = 11; means ± SD). (B) Engraftment of GFP+ 
HSCs in the KLS fraction (Sca1+ c-kit+ HSCs 
from lineage-negative selected BM) or in total 
BM, spleen, and thymus of WT HSCT and KO 
HSCT mice (means ± SD). (C) Erythroid differ-
entiation in BM and spleen (D) of WT HSCT 
and KO HSCT mice. (E) Different stages of  
B cell maturation were defined according to 
expression of IgM, B220, and CD127 markers 
(means ± SD). (F and G) Percentage of lymphoid 
B220+ cells in spleen (F) and (G) percentage of 
thymocyte subsets in WT HSCT and KO HSCT 
mice. Charts: each dot represents one mouse, 
means are shown. Unpaired Student’s t test 
statistical analysis was performed, and p-values 
are reported when significant. The transplan-
tation experiment was performed two times.
Figure 9.  HSC and progenitor character-
ization in recipients of GFP-expressing 
Sumf1/ HSPCs. (A) GFP+ Sca1+ c-kit+ HSCs 
in lineage-negative selected BM of recipient 
of WT (n = 8) and KO (n = 11) HSCT (WT-HSCT 
and KO-HSCT mice). Each dot represents one 
mouse. Mean ± SD are shown; mean of two 
independent experiments. (B) LT-HSCs (GFP+ 
CD150+ KLS) from WT-HSCT and KO-HSCT 
(each dot represents a pool of two mice).  
(C) CLPs, CMPs, MEPs, and GMPs in BM of WT 
and KO HSCT mice expressed as fold to WT 
average. (means ± SD; n = 6; analysis of two 
independent experiments). Mann-Whitney 
test statistical analysis was performed, and  
p-values are reported when significant.1656 Sumf1 controls hematopoiesis | Buono et al.
gether  with  some  additional  growth  factors  and  cytokines 
(Yeoh et al., 2006). In contrast, TGF- is generally accepted 
to be a potent inhibitor of HSC expansion in vitro (Sitnicka 
et al., 1996; Batard et al., 2000).
So,  overall,  very  little  is  known  about  the  cross-talk   
between these signaling pathways. It is certain that the influ-
ences they have on each other will finally regulate the 
complex  hierarchical  development  of  different  blood  lin-
eages. If one signaling pathway is imbalanced or dysregulated, 
it might lead to cells of one lineage being reprogrammed into 
another lineage, thus resulting in a change in cell fate. This 
can arise from aberrant expression of key transcription fac-
tors, such as GATA-1, GATA-3, C/EBP, and PU.1 (Orkin 
and Zon, 2008). Indeed, it has been shown that myeloid 
transdifferentiation of pro–B cells is caused by ectopic ex-
pression of c/EBP (Heavey et al., 2003). This might also 
account for the compensation of the granulocytes that we see 
in the Sumf1/ mice.
Here, we have shown direct interconnections between at 
least  three  different  pathways:  FGF,  Wnt/-catenin,  and 
Notch  signaling.  These  are  regulated  by  the  activity  of 
SUMF1, probably via the Sulf1 and Sulf2 sulfatases. We have 
shown that activation of the FGF signaling pathway leads to 
increases in ERK phosphorylation that, upon GSK-3 inacti-
vation, trigger -catenin accumulation. In thymocytes, we 
observed  FGF-dependent  accumulation  of  -catenin  and 
Notch activation. Interestingly, SUMF1 controls autophagy, 
proliferation, and differentiation of chondrocytes by limiting 
FGF signaling (Settembre et al., 2008). The constitutive acti-
vation of FGF and Wnt/-catenin leads to an increase   
in  ST-HSCs,  as  clearly  seen  in  the  recipient  transplanted 
mice. As a result, a lack of terminally differentiated cells oc-
curs because of developmental failure in the three lineages; in 
addition, aberrant thymocytes also develop. The concerted 
activities of accumulated -catenin and Notch1 might, in part, 
stall the transition of thymocytes from the double-negative   
to the DP stage, and increase the levels of SP CD4+ or CD8+ 
thymocytes; indeed, it has been shown that -catenin can,   
in part, transcribe the CD4 gene (Huang et al., 2006) and in-
crease the timing and maturation rate of CD8+ cells (Yu and 
Sen, 2007; Staal and Sen, 2008). The rescue of erythroid lin-
eage differentiation and the normal development of T lym-
phocytes after FGF1 signaling inhibition in Sumf1/ mice 
further reinforce the observation that FGF activation controls 
Wnt and Notch signaling activation in the differentiation   
of HSPCs.
In the Sulf2/ mice, there was a slight increase in pro-
erythroblasts,  a  small  decrease  in  BM  B  mature  cells,  a   
decrease in DP thymocytes, and an increase in SP CD4+ cells, 
and we would expect lineage defects to be even more severe 
in the Sulf1/ Sulf2/ double-KO mice because of the re-
dundancy in the activities of these two sulfatases (Ratzka   
et al., 2008). This double-KO phenotype is very severe and 
the mice die very early (Holst et al., 2007); indeed, we only 
obtained a sufficient number of these Sulf1/ Sulf2/ dou-
ble-KO  mice  for  the  biochemical  analysis  here.  Sulf1/ 
leading us to conclude that SUMF1 has an important role 
in  different  steps  of  the  lineage  differentiation  process   
of HSPCs.
DISCUSSION
HSCs represent a rare population of adult stem cells that can 
give rise to all blood cell lineages in a hierarchical process that 
occurs  daily  in  adult  mammals  (Morrison  and  Weissman, 
1994; Morrison et al., 1995; Kondo et al., 1997; Akashi et al., 
2000; Laiosa et al., 2006a). The more the cells proceed in the 
developmental progression, the more restricted they become 
in  their  differentiation  potential,  losing  their  self-renewal 
ability.  Cytokines,  hormones,  and  activation  of  different   
signaling pathways control these well-tuned developmental 
processes  that  couple  and  integrate  extrinsic  and  intrinsic   
fate  determinants.  Developmentally  conserved  signaling 
pathways have emerged as important controlling devices for 
HSC  fate,  including  Wnt,  FGF,  Notch,  sonic  hedgehog 
(Shh), and bone morphogenetic protein (BMP; Esko and 
Lindahl, 2001).
Several studies have reported on the role of the Wnt/ 
-catenin pathway in controlling self-renewal and differenti-
ation of HSCs in vivo and ex vivo, with apparent discrepan-
cies seen. Some studies claim that stabilization of -catenin is 
positive for self-renewal and differentiation of HSCs (Reya   
et al., 2003; Willert et al., 2003; Baba et al., 2005), whereas 
others assert that -catenin stabilization impairs HSC repop-
ulation and engraftment in a recipient (Kirstetter et al., 2006; 
Scheller et al., 2006). We believe that fixed -catenin thresh-
olds at specific developmental stages can provide different 
phenotypes. This is evident in different biological contexts, 
such as during cardiac differentiation: differentiating embry-
onic stem cells treated early with Wnt-3a undergo cardiac 
differentiation; conversely, late activation of the Wnt path-
way reduces their cardiac differentiation (Ueno et al., 2007). 
Periodic -catenin accumulation in embryonic stem cells at a 
specific threshold can lead to reprogramming of somatic cells 
after fusion. In contrast, high or low levels of -catenin can 
affect the ability of embryonic stem cells to reprogram so-
matic cells (Lluis et al., 2008).
This scenario is even further complicated, as many signal-
ing pathways show cross-talk, and their interactions will de-
termine the different developmental fates in blood lineages. 
An interaction between the Shh and BMP-4 pathways is evi-
dent in the finding that Shh can induce proliferation of primi-
tive hematopoietic cells via BMP-4 (Bhardwaj et al., 2001). 
However, BMP-4 can maintain HSCs in culture, but cannot 
control their expansion (Utsugisawa et al., 2006). FGFs and 
Wnts have also been shown to interact in a variety of devel-
opmental systems, including brain, kidney, and tooth in some 
vertebrates (Moon et al., 1997), and FGF signaling controls 
proliferation and subsequent lineage commitment of neural 
stem cells through a concerted action with -catenin (Israsena 
et al., 2004). The role of the FGF signaling pathway in the 
development of blood lineages is poorly understood, with 
FGF1 and FGF2 used for ex vivo culture of LT-HSCs, to-JEM VOL. 207, August 2, 2010 
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MATERIALS AND METHODS
Mice. The strains used in this study were as follows: Sumf1/ (Settembre   
et al., 2007), Sulf1/, Sulf2/ (Ai et al., 2003), Ids/ (Cardone et al., 
2006), and Sgsh/ (Fraldi et al., 2007). All the procedures were approved by 
the Animal care and use Committee of Telethon Institute of Genetics and 
Medicine and were communicated to the Ministry of Health and local   
authorities, according to Italian law.
Flow cytometry analysis. A FACSCanto instrument (BD) was used 
for the FACS analysis. Phycoerythrin-conjugated anti–mouse mAbs to 
c-kit, CD34, CD71, CD3, CD4, IgM, and Gr-1; allophycocyanin-conjugated 
anti–mouse mAbs to Ter119, CD11b, CD16, CD25, and CD8; and 
phycoerythrin-conjugated-cycrome5 anti–mouse mAbs to B220, CD3, 
and 7-amino-actinomycin D were purchased from BD. Phycoerythrin-
conjugated-cycrome7 anti–mouse mAbs to Sca1 and c-kit; allophyco-
cyanin-conjugated-Alexa Fluor 750 anti–mouse mAbs to c-kit and CD8; 
and allophycocyanin-conjugated CD150 were purchased from eBioscience. 
The FITC-conjugated anti–mouse mAb to CD127 was purchased from 
Abcam, and the phycoerythrin-conjugated anti–mouse mAb to CD115 
was purchased from Serotec. Isolated BM, spleen, and thymic cells were 
prepared for flow cytometry by blocking the aspecific sites using anti-Fc 
blocking reagent from BD, and then incubating the cells with the appro-
priate  antibodies  or  control  isotype-matched  antibodies,  followed  by 
PBS washes.
HSPC transplantation. 2-mo-old C57Bl6 mice were lethally irradiated 
for 4 h before transplantation (10 Gy, divided into two doses). Next, 7 × 105 
WT or Sumf1/-transduced HSPCs were injected into the tail veins of the 
recipient mice. The transplanted mice were sacrificed 10 wk after transplan-
tation, and their BM, spleen, and thymus were analyzed.
Statistics. Analyses were performed by one-way and two-way ANOVA, 
using Bonferroni correction as post-test, or Student’s t test/Mann Whitney 
tests, and the data are expressed as means ± SD; p-values < 0.05 were con-
sidered statistically significant.
Purification and culture of mouse HSPCs. Total BM was flushed 
out  from  femurs  and  tibia  of  3-wk-old  and  age-matched  WT  and 
Sumf1/ mice. For in vitro experiments, the lineage-fraction was puri-
fied from total BM cells by untouched isolation on a magnetic sorter, using 
the Lineage Depletion kit (Miltenyi Biotec), according to the manufacturer 
protocol. The HSPCs were cultured for two days in Stem Span Sfem 
medium (STEMCELL Technologies) at a concentration of 106 cells/ml 
in the presence of 100 ng/ml recombinant mouse SCF (R&D Systems),   
20 ng/ml mouse IL3 (Peprotech), 20 ng/ml human IL6 (Peprotech), and 
10 ng/ml Flt3 ligand (Peprotech). They were then harvested for all of the 
analyses. HSPCs for the in vivo studies were purified from total BM cells 
by untouched isolation using the Murine Progenitor Enrichment Cocktail 
(STEMCELL Technologies).
Purification and culture of mouse mesenchymal stromal cells. Total 
BM was flushed out from femurs and tibia of 3-wk-old and age-matched 
WT and Sumf1/ mice. The total cells were cultured for 3 d in DME with 
10% FBS. The medium was then changed to remove nonadherent cells. The 
mesenchymal stromal cells (MSCs) were grown until confluence, and then 
harvested for analysis.
Splenocyte and thymocyte isolation. Splenocytes were obtained by me-
chanic disaggregation of the spleen in RPMI with 10% FBS, 100 IU/ml 
penicillin, 100 µg/ml streptomycin, 2 mM l-glutamine, supplemented with 
28.4 mM 2-mercaptoethanol. The thymocytes were obtained by mechanic 
disaggregation of the thymus in IMDM with 20% FBS, 100 IU/ml penicil-
lin, 100 µg/ml streptomycin, and 2 mM l-glutamine. After centrifugation at 
1,500 rpm for 5 min at room temperature, 2.5 ×103 cells were resuspended 
in 50 µl blocking solution.
Sulf2/ HSPCs showed constitutive activation of FGF and 
Wnt signalings. Unfortunately, because of the severe pheno-
type and the lack of Sulf1/ Sulf2/ double-KO mice, we 
could not carry out the BM phenotype analysis. In contrast, 
Ids/ and Sgsh/ mice did not show any of the defects seen 
in the Sumf1/ strain, ruling out any involvement of these 
other sulfatases in the hematopoietic lineage phenotype.
Mesenchymal stromal cells (MSCs) reside in the niche 
that supports stem cell activity in vivo. MSCs from Sumf1/ 
mice show constitutive activation of the FGF and Wnt sig-
naling pathways. These might induce irreversible conditioned 
functions in the HSCs. Osteoblasts overexpressing the Wnt 
inhibitor Dkk1 have irreversible effects on HSC function, 
reducing  their  ability  for  long-term  repopulation  in  serial 
transplant experiments (Fleming et al., 2008). It is possible 
that concerted dysregulation of the FGF, Wnt/-catenin, 
and Notch signaling pathways in both the MSC niche com-
ponent and in the HSCs themselves forces the HSC pool to 
enter into the cell cycle, and thus to switch them toward a 
short-term reconstituting phenotype, with a consequent de-
crease in terminally mature cell development.
Moreover, we have also show that these altered interacting 
signaling pathways induce lineage defects in a mouse model of 
MSD. Patients affected by MSD show a lack of activity of their 
entire family of sulfatases, and the consequent accumulation of 
undegraded sulfatase substrates in their lysosomes. In addition, 
these patients have developmental problems that can be as-
cribed to a lack of activity of Sulf1 and Sulf2, the only sulfatases 
that can modulate signaling pathways. The lysosomal storage in 
murine models of sulfatase deficiencies does not cause defects 
in lineage development. In further support of these data, we 
recently showed that invariant natural killer T cells develop 
aberrantly only in the MSD mouse model, and not in lyso-
somal disease models (Plati et al., 2009), ruling out a role for 
lysosomal engulfment in lineage development.
Sulf1/  Sulf2/  double-KO  mice  and  Sumf1/  mice 
show very high perinatal mortality (Holst et al., 2007), and our 
data lead us to believe that blood lineage failure might contribute 
to this mortality. Alternatively, the MSD disease is very hetero-
geneous with respect to the developmental features, which is 
possibly caused by the escape of -catenin stabilization in pa-
tients carrying less-detrimental SUMF1 mutations. Interestingly, 
we observed that even in mixed background strains, the BM 
phenotype of Sumf1/ mice is relatively heterogeneous, with 
some mice showing less severe defects (unpublished data).
All in all, our data highlight that regulation through the 
sulfation state of the HSPGs, which provide a repository of 
growth factors such as Wnt and FGF, should be finely tuned. 
This is also modulated by the Sulf activities (Dhoot et al., 
2001; Ai et al., 2003; Viviano et al., 2004; Wang et al., 
2004). Thus, we hypothesize that only a small fraction of 
Sulf proteins have the FGly residue and can cleave the sulfate 
of the heparan sulfate in HSPGs; the majority of the Sulfs 
should  be  activated  by  SUMF1.  This  represents  a  fine   
regulation mechanism, and SUMF1 appears to be the master 
controlling factor here.1658 Sumf1 controls hematopoiesis | Buono et al.
centrifuged to remove the excess SU5402, washed twice in PBS, and resus-
pended in 100 µl PBS, for i.p. injection.
Gating strategies. Gating strategies for stem cells and progenitors were ap-
plied according to the Weissman Laboratory protocol (Irving L. Weissman, 
Institute of Stem Cell Biology and Regenerative Medicine, Stanford Cancer 
Center, Stanford University School of Medicine, Stanford, CA). In brief, the 
following populations were identified: KLS, staining was performed on lin-
eage-selected cells, with KLS cells defined as c-kit+, Sca1+; CLPs, staining was 
performed on lineage-selected cells, with CLP cells defined as c-kit+, Sca1+, 
CD127+; CMPs, staining was performed on lineage-selected cells, with CMP 
cells defined as c-kit+, Sca1, CD127, Cd34+, CD16low; MEPs, staining was 
performed on lineage-selected cells, with MEPs defined as c-kit+, Sca1, 
CD127, CD34, CD16+/low; GMPs, staining was performed on lineage- 
selected cells, with GMPs defined as c-kit+, Sca1, CD127, Cd34+, CD16high; 
pro–B cells, staining was performed on total BM, with pro–B cells defined as 
B220+/low, IgM, CD127+; immature B cells, staining was performed on total 
BM, with immature B cells defined as B220+/low, IgM+; mature B cells, stain-
ing was performed on total BM, with mature B cells defined as B220bright, 
IgM+/; pro–T cells, staining was performed on total BM, with pro–T cells 
defined as CD127+, CD3, CD4, CD8-/low, CD25, c-kit+.
Clonogenic  assay.  Colony-forming  assays  were  performed  by  plating   
5 × 103 untransduced or transduced, WT, and Sumf1/ HSPCs in methyl-
cellulose  medium  (mouse  MethoCult;  Stem  Cell  Technologies)  supple-
mented with cytokines. After 1 wk, the colonies were scored under light or 
fluorescence microscopy, to evaluate the percentages of GFP+ cells.
Online supplemental material. Fig. S1 shows the Western blot analysis 
of phospho-FSR2 and (Glypican 3) GPC3 mRNA in WT and Sumf1/ 
HSPCs. Fig. S2 shows GATA­1 and c/EBP mRNA expression in WT 
and Sumf1/ HSPCs. Fig. S3 shows the analysis of BM, spleen, and thymus 
cellularity in WT, Sumf1/, Ids/, Sulf1/, and Sulf2/ mice. Fig. S4   
shows analysis of the erythroid lineage in Ids/, Sulf1/, and Sulf2/ 
mice. Fig. S5 shows analysis of lymphoid lineage in Ids/, Sulf1/, and 
Sulf2/ models. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20091022/DC1.
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